ArticleActa neurochirurgica2025
Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67.
Article in Acta neurochirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outcomes of early versus late radiotherapy in grade 2 meningiomas: a National retrospective analysis from the TROD neuro-oncology group.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGiven the heterogeneity of atypical meningioma (AM) and potential interobserver variability in WHO grade assignment among pathologists, there is a need for more objective criteria to improve risk stratification. This study examined conventional and novel risk factors for AM progression, focusing on mitotic count (MC) and Ki-67, and explored their clinical relevance.
methodsThis retrospective cohort study included 240 consecutive patients with AM surgically treated at a single tertiary institution between 2001 and 2020. The cut-off values for MC and Ki-67 were determined using the Youden index. Risk factors for progression were analyzed using cause-specific Cox proportional hazards models. Progression-free survival (PFS) was estimated using cumulative incidence function (CIF) and compared using the Gray's test.
resultsAM progression occurred in 32.5% of patients with a median time to progression of 25.2 months. The median follow-up was 42.3 months. While a clinically meaningful Ki-67 cut-off was not identified, MC ≥ 6 was significantly associated with AM progression. On multivariate analysis, age, gross total resection (GTR), MC ≥ 6, brain invasion, sheeting, and adjuvant radiotherapy (RTx) were associated with progression. RTx improved PFS in the subtotal resection (STR) group but not in the GTR group. Among GTR patients, those with MC ≥ 6 had worse outcomes.
conclusionGTR and RTx may reduce the progression of AM. MC ≥ 6 significantly increases the risk of progression, even in GTR patients. RTx should be considered for all STR patients A more vigilant follow-up or consideration of RTx is warranted in GTR patients when a high MC is identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.